Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dexlansoprazole OD Tablets vs Capsules
NCT02064907Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 5, Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration at Day 5 and 2 more. Started Feb 2014; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02064907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064907.